Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110


Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest.

Al Sawah E, Chen X, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, Bou Zgheib N, Chon HS, Wenham RM, Apte SM, Judson PL, Lancaster JM.

Gynecol Oncol. 2013 Oct;131(1):207-12. doi: 10.1016/j.ygyno.2013.07.088.


Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.

Sasano T, Mabuchi S, Kuroda H, Kawano M, Matsumoto Y, Takahashi R, Hisamatsu T, Sawada K, Hashimoto K, Isobe A, Testa JR, Kimura T.

Mol Cancer Res. 2015 Apr;13(4):795-806. doi: 10.1158/1541-7786.MCR-14-0314.


Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.

Engel JB, Honig A, Schönhals T, Weidler C, Häusler S, Krockenberger M, Grunewald TG, Dombrowski Y, Rieger L, Dietl J, Wischhusen J.

Eur J Obstet Gynecol Reprod Biol. 2008 Nov;141(1):64-9. doi: 10.1016/j.ejogrb.2008.06.007.


The Chinese herb polyphyllin D sensitizes ovarian cancer cells to cisplatin-induced growth arrest.

Al Sawah E, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, Boac BM, Bush SH, Bou Zgheib N, McClung EC, Khulpateea BR, Berry A, Hakam A, Wenham RM, Lancaster JM, Judson PL.

J Cancer Res Clin Oncol. 2015 Feb;141(2):237-42. doi: 10.1007/s00432-014-1797-x.


Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma.

Pinton G, Manente AG, Angeli G, Mutti L, Moro L.

PLoS One. 2012;7(5):e36856. doi: 10.1371/journal.pone.0036856.


The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma.

Kumar A, Fillmore HL, Kadian R, Broaddus WC, Tye GW, Van Meter TE.

Mol Cancer Res. 2009 Nov;7(11):1813-21. doi: 10.1158/1541-7786.MCR-09-0069.


Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers.

Engel JB, Schönhals T, Häusler S, Krockenberger M, Schmidt M, Horn E, Köster F, Dietl J, Wischhusen J, Honig A.

Arch Gynecol Obstet. 2011 Mar;283(3):603-10. doi: 10.1007/s00404-010-1457-6.


Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.

Kawaguchi H, Terai Y, Tanabe A, Sasaki H, Takai M, Fujiwara S, Ashihara K, Tanaka Y, Tanaka T, Tsunetoh S, Kanemura M, Ohmichi M.

J Ovarian Res. 2014 Apr 9;7:38. doi: 10.1186/1757-2215-7-38.


In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine.

Li Z, Tan F, Liewehr DJ, Steinberg SM, Thiele CJ.

J Natl Cancer Inst. 2010 Jun 2;102(11):758-70. doi: 10.1093/jnci/djq125.


In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival.

Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Fulp W, Cubitt CL, Chen DT, Lancaster JM.

Br J Cancer. 2012 Jun 5;106(12):1967-75. doi: 10.1038/bjc.2012.207.


Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.

Tsunetoh S, Terai Y, Sasaki H, Tanabe A, Tanaka Y, Sekijima T, Fujioka S, Kawaguchi H, Kanemura M, Yamashita Y, Ohmichi M.

Cancer Biol Ther. 2010 Dec 1;10(11):1137-46. doi: 10.4161/cbt.10.11.13443.


Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth.

Liang S, Guo R, Zhang Z, Liu D, Xu H, Xu Z, Wang X, Yang L.

Oncol Rep. 2013 Jun;29(6):2422-30. doi: 10.3892/or.2013.2397.


Perifosine: update on a novel Akt inhibitor.

Gills JJ, Dennis PA.

Curr Oncol Rep. 2009 Mar;11(2):102-10. Review.


AEG-1 is a target of perifosine and is over-expressed in gastric dysplasia and cancers.

Huang W, Yang L, Liang S, Liu D, Chen X, Ma Z, Zhai S, Li P, Wang X.

Dig Dis Sci. 2013 Oct;58(10):2873-80. doi: 10.1007/s10620-013-2735-5.


BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.

Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, Berchuck A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Bloom GC, Eschrich SA, Sebti S, Chen DT, Lancaster JM.

Clin Cancer Res. 2011 Oct 1;17(19):6356-66. doi: 10.1158/1078-0432.CCR-11-0735.


The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism.

Chiarini F, Del Sole M, Mongiorgi S, Gaboardi GC, Cappellini A, Mantovani I, Follo MY, McCubrey JA, Martelli AM.

Leukemia. 2008 Jun;22(6):1106-16. doi: 10.1038/leu.2008.79.


Preclinical evaluation of perifosine as a potential promising anti-rhabdomyosarcoma agent.

Shen J, Hong Y, Zhao Q, Zhang JL.

Tumour Biol. 2016 Jan;37(1):1025-33. doi: 10.1007/s13277-015-3740-4.


The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer.

Bou Zgheib N, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Cubitt CL, Chen DT, Lancaster JM.

Int J Oncol. 2012 Jul;41(1):179-88. doi: 10.3892/ijo.2012.1451.


Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition.

Sun H, Yu T, Li J.

Cancer Lett. 2011 Nov 1;310(1):118-28. doi: 10.1016/j.canlet.2011.06.010.


Supplemental Content

Support Center